June 27, 2016 04:28 PM EDT
Pharma

Reg­u­lus craters af­ter FDA slaps a hold on hep C RNA drug fol­low­ing 2nd case of jaun­dice

John Carroll

Editor & Founder

Just days af­ter set­ting up a $30 mil­lion line of cred­it to ramp up work on its he­pati­tis C ther­a­py RG-101, Reg­u­lus Ther­a­peu­tics has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pur­due, Sack­lers reach new $7.4B opi­oid set­tle­ment af­ter SCO­TUS re­jec­tion

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

As an­oth­er Trump term gets un­der­way, phar­ma ad­vi­sors get com­fort­able with un­cer­tain­ty

Ab­b­Vie part­ners with Neo­morph in lat­est mol­e­c­u­lar glue deal

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times